Cardiac imaging software provider Heartflow applies for a US IPO, aiming to raise $100 million
Heartflow, a supplier of cardiac imaging software, submitted an IPO application to the SEC on Thursday Eastern Time, planning to raise up to $100 million. The company focuses on imaging and diagnostics for coronary artery disease and has served over 400,000 patients. Heartflow utilizes artificial intelligence and computational fluid dynamics technology to create personalized 3D heart models. Founded in 2007, the company plans to list on NASDAQ under the ticker symbol HTFL, with JPMorgan Chase and others serving as co-book runners
According to the Zhitong Finance APP, Heartflow (HTFL.US), a provider of imaging and diagnostic software focused on coronary artery disease assessment, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, Eastern Time, planning to raise up to $100 million through an initial public offering (IPO).
Heartflow offers a non-invasive solution for diagnosing and managing coronary artery disease (CAD). As of March 31, 2025, the Heartflow platform has been used to assess over 400,000 patients with coronary artery disease, with 132,000 patients benefiting in just the year 2024.
This innovative platform utilizes artificial intelligence and advanced computational fluid dynamics technology to create personalized 3D models of patients' hearts and provides actionable insights regarding blood flow, vascular narrowing, plaque volume, and plaque composition.
The company, headquartered in Mountain View, California, was founded in 2007 and achieved revenue of $136 million in the 12 months ending March 31, 2025. The company plans to list on NASDAQ under the ticker symbol HTFL.
Heartflow confidentially submitted its listing application on February 6, 2025, with JPMorgan Chase, Morgan Stanley, and Piper Sandler serving as co-bookrunners for the transaction. The company has not yet disclosed pricing terms
